Welcome to Ashvattha
Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases. We believe that HDTs will become the future of targeted therapeutics and unlock new levels of patient care.
Jeffrey Cleland, Ph.D., Ashvattha Chairman, CEO and President interview with Health Professional Radio, July 1, 2021
"Potential COVID Treatments That Address Brain Inflammation"
Our solution enables patient selection followed by treatment with anti-neuroinflammatory agent coupled to HDT to target reactive microglia
We have designed and optimized an HDT that precisely targets reactive macrophages and retinal pigment epithelial cells (RPEs) after systemic administration
Neurologists test novel compound for lung and brain injury in severe COVID-19 patients (UT Health News)
Neurologists are researching whether a novel immunomodulatory treatment, OP-101, an investigational compound developed by Ashvattha Therapeutics, can dampen lung and brain injury in hospitalized COVID-19 patients through a clinical trial at The University of Texas Health Science Center at Houston.
Ashvattha Therapeutics Announces Two Oral Presentations at the World Molecular Imaging Congress 2021
Ashvattha will present two oral presentations at the virtual World Molecular Imaging Congress (WMIC), on October 5-8, 2021.
Ashvattha Chairman, CEO and President Jeffrey Cleland, Ph.D., will be presenting at various virtual and in-person investor conferences in September and October.
Ashvattha Therapeutics Announces Positive Interim Data from Ongoing Phase 2 PRANA Clinical Study of OP-101 in Severe COVID-19 Patients
Ashvattha announced positive interim results from its ongoing multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hyperinflammation in hospitalized adults with severe COVID-19.
Ashvattha will present at the Sachs 7th Annual Immuno-Oncology Innovation Forum, held virtually on May 18-20